Noncoding RNAs in alcoholic liver disease

Li, Hai‐Di; Du, Xiao‐Sa; Chen, Xin; Yang, Yang; Huang, Cheng; Meng, Xiao‐Ming; Li, Jun

doi:10.1002/jcp.28229

Cited by 16 publications

(8 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, miR-155 aggravated lipopolysaccharide (LPS)-induced inflammatory responses 9 , while the inhibition of miR-155 ameliorated macrophage inflammation 10 . In addition, miR-155 has been intensively studied for the treatment of hepatic fibrosis because it targets several fibrogenesis genes 8 , 11 , 12 .…”

Section: Introductionmentioning

confidence: 99%

The antimicrobial peptide YD attenuates inflammation via miR-155 targeting CASP12 during liver fibrosis

Wang

Chen

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

The antimicrobial peptide APKGVQGPNG (named YD), a natural peptide originating from Bacillus amyloliquefaciens CBSYD1, exhibited excellent antibacterial and antioxidant properties in vitro . These characteristics are closely related to inflammatory responses which is the central trigger for liver fibrosis. However, the therapeutic effects of YD against hepatic fibrosis and the underlying mechanisms are rarely studied. In this study, we show that YD improved liver function and inhibited the progression of liver fibrosis by measuring the serum transaminase activity and the expression of α -smooth muscle actin and collagen I in carbon tetrachloride-induced mice. Then we found that YD inhibited the level of miR-155, which plays an important role in inflammation and liver fibrosis. Bioinformatics analysis and luciferase reporter assay indicate that Casp12 is a new target of miR-155. We demonstrate that YD significantly decreases the contents of inflammatory cytokines and suppresses the NF- κ B signaling pathway. Further studies show that transfection of the miR-155 mimic in RAW264.7 cells partially reversed the YD-mediated CASP12 upregulation, the downregulated levels of inflammatory cytokines, and the inactivation of the NF- κ B pathways. Collectively, our study indicates that YD reduces inflammation through the miR-155– Casp12 –NF- κ B axis during liver fibrosis and provides a promising therapeutic candidate for hepatic fibrosis.

show abstract

Section: Introductionmentioning

confidence: 99%

The antimicrobial peptide YD attenuates inflammation via miR-155 targeting CASP12 during liver fibrosis

Wang

Chen

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

“…ALD is a complex disease caused by prolonged and heavy alcohol consumption, along with predisposing genetic factors. ALD can cause liver dysfunction, including steatohepatitis, fibrosis, cirrhosis, and eventually HCC [ 102 ]. There is tremendous evidence of the effects of miRNA dysregulation on the pathogenesis and development of ALD, such as liver damage, lipid metabolism dysfunction, inflammation, oxidative stress, apoptosis, and fibrosis [ 102 ].…”

Section: Roles Of Mirnas In Various Liver Diseases Leading To Hccmentioning

confidence: 99%

“…ALD can cause liver dysfunction, including steatohepatitis, fibrosis, cirrhosis, and eventually HCC [ 102 ]. There is tremendous evidence of the effects of miRNA dysregulation on the pathogenesis and development of ALD, such as liver damage, lipid metabolism dysfunction, inflammation, oxidative stress, apoptosis, and fibrosis [ 102 ]. Inflammation-related miRNAs, such as miR-132, miR-155, miR-146, and miR-21, influence alcohol/lipopolysaccharide (LPS)/TLR4 pathways.…”

Section: Roles Of Mirnas In Various Liver Diseases Leading To Hccmentioning

confidence: 99%

MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review

Morishita

Oura

Tadokoro

et al. 2021

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the seventh most frequent cancer and the fourth leading cause of cancer mortality worldwide. Despite substantial advances in therapeutic strategies, the prognosis of late-stage HCC remains dismal because of the high recurrence rate. A better understanding of the etiology of HCC is therefore necessary to improve outcomes. MicroRNAs (miRNAs) are small, endogenous, noncoding, single-stranded RNAs that modulate the expression of their target genes at the posttranscriptional and translational levels. Aberrant expression of miRNAs has frequently been detected in cancer-associated genomic regions or fragile sites in various human cancers and has been observed in both HCC cells and tissues. The precise patterns of aberrant miRNA expression differ depending on disease etiology, including various causes of hepatocarcinogenesis, such as viral hepatitis, alcoholic liver disease, or nonalcoholic steatohepatitis. However, little is known about the underlying mechanisms and the association of miRNAs with the pathogenesis of HCC of various etiologies. In the present review, we summarize the key mechanisms of miRNAs in the pathogenesis of HCC and emphasize their potential utility as valuable diagnostic and prognostic biomarkers, as well as innovative therapeutic targets, in HCC diagnosis and treatment.

show abstract

“…miRNAs are single-stranded, 19–22 nucleotide non-coding sequences that bind to the complementary sequence of messenger RNA molecules, regulating their function by inhibiting or silencing translation [ 69 ]. As shown in Table 1 , the dysregulation of miRNAs correlates with ALD severity and prognosis via regulation of multiple functions, including intestinal permeability change, liver steatosis and fibrosis, and oxidative stress [ 8 , 16 , 70 ]. Other epigenetic mechanisms include acetylation and methylation of DNA mediated by ethanol [ 71 ].…”

Section: Pathophysiologymentioning

confidence: 99%

Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives

Liu

Tsai

Hsu

2021

IJMS

View full text Add to dashboard Cite

Alcohol-related liver disease (ALD) refers to the liver damage occurring due to excessive alcohol consumption and involves a broad spectrum of diseases that includes liver steatosis, steatohepatitis, hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). The progression of ALD is mainly associated with the amount and duration of alcohol usage; however, it is also influenced by genetic, epigenetic, and environmental factors. The definite diagnosis of ALD is based on a liver biopsy, although several non-invasive diagnostic tools and serum biomarkers have emerging roles in the early detection of ALD. While alcohol abstinence and nutritional support remain the cornerstone of ALD treatment, growing evidence has revealed that the therapeutic agents that target oxidative stress or gut-liver axis, inflammatory response inhibition, and liver regeneration enhancement also play a role in ALD management. Furthermore, microRNAs modulation and mesenchymal stem cell-based therapy have emerging potential as ALD therapeutic options. This review summarizes the updated understanding of the pathophysiology, diagnosis, and novel therapeutic approaches for ALD.

show abstract

Noncoding RNAs in alcoholic liver disease

Cited by 16 publications

References 97 publications

The antimicrobial peptide YD attenuates inflammation via miR-155 targeting CASP12 during liver fibrosis

The antimicrobial peptide YD attenuates inflammation via miR-155 targeting CASP12 during liver fibrosis

MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review

Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives

Contact Info

Product

Resources

About